Immunotherapy for Advanced Prostate Cancer

Overview

Journal Rev Urol

Date 2007 Mar 28

PMID 17387370

Citations 9

Authors

Johannes Vieweg

Affiliations

Soon will be listed here.

Abstract

The absence of curative therapies for advanced or recurrent forms of prostate cancer mandates continued development of novel, more effective treatment regimens. Due to recent advances in basic and translational research, therapeutic vaccines and monoclonal antibody-based therapies are steadily gaining ground as promising treatment modalities against prostate cancer. Several immunotherapeutic products have recently been investigated in later-phase trials and have reported evidence for clinical benefit while maintaining an excellent quality of life for participants. The cumulative clinical results available to date indicate that immune-based therapies will likely play a role in the treatment of patients with prostate and other malignancies. The objective of this article is to increase awareness of contemporary immunologic therapies and clinical trials of new biologic reagents against prostate cancer. We also seek to encourage urologists to actively participate in clinical trials and evaluate the potential of immunotherapeutic drugs for impacting standards of care.

Citing Articles

Cell growth inhibition and apoptotic effects of a specific anti-RTFscFv antibody on prostate cancer, but not glioblastoma, cells.

Nejatollahi F, Bayat P, Moazen B F1000Res. 2017; 6:156.

PMID: 28491282 PMC: 5399964. DOI: 10.12688/f1000research.10803.1.

Immune Cell-Conditioned Media Suppress Prostate Cancer PC-3 Cell Growth Correlating With Decreased Proinflammatory/Anti-inflammatory Cytokine Ratios in the Media Using 5 Selected Crude Polysaccharides.

Lin H, Lin J Integr Cancer Ther. 2016; 15(4):NP13-NP25.

PMID: 27130724 PMC: 5739154. DOI: 10.1177/1534735415627923.

HLA Class II Antigen Presentation in Prostate Cancer Cells: A Novel Approach to Prostate Tumor Immunotherapy.

Doonan B, Haque A Open Cancer Immunol J. 2013; 3:1-7.

PMID: 24163711 PMC: 3807132. DOI: 10.2174/1876401001003010001.

Human prostatic acid phosphatase: structure, function and regulation.

Muniyan S, Chaturvedi N, Dwyer J, LaGrange C, Chaney W, Lin M Int J Mol Sci. 2013; 14(5):10438-64.

PMID: 23698773 PMC: 3676848. DOI: 10.3390/ijms140510438.

Castration-resistant prostate cancer: potential targets and therapies.

Parray A, Siddique H, Nanda S, Konety B, Saleem M Biologics. 2012; 6:267-76.

PMID: 22956858 PMC: 3430091. DOI: 10.2147/BTT.S23954.

References

Toi M, Horiguchi K, Bando H, Saji S, Chow L . Trastuzumab: updates and future issues. Cancer Chemother Pharmacol. 2005; 56 Suppl 1:94-9. DOI: 10.1007/s00280-005-0110-8. View

Bonnotte B, Gough M, Phan V, Ahmed A, Chong H, Martin F . Intradermal injection, as opposed to subcutaneous injection, enhances immunogenicity and suppresses tumorigenicity of tumor cells. Cancer Res. 2003; 63(9):2145-9. View

Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G . Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother. 2003; 53(2):64-72. PMC: 11032848. DOI: 10.1007/s00262-003-0443-2. View

Polanczyk M, Carson B, Subramanian S, Afentoulis M, Vandenbark A, Ziegler S . Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol. 2004; 173(4):2227-30. DOI: 10.4049/jimmunol.173.4.2227. View

Kane M . Global control of primary hepatocellular carcinoma with hepatitis B vaccine: the contributions of research in Taiwan. Cancer Epidemiol Biomarkers Prev. 2003; 12(1):2-3. View

Simons J, Mikhak B, Chang J, DeMarzo A, Carducci M, Lim M . Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 1999; 59(20):5160-8. View

Allison J, Chambers C, Hurwitz A, Sullivan T, Boitel B, Fournier S . A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance?. Novartis Found Symp. 1998; 215:92-8; discussion 98-102, 186-90. DOI: 10.1002/9780470515525.ch7. View

Pardoll D, Allison J . Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med. 2004; 10(9):887-92. DOI: 10.1038/nm0904-887. View

DeBenedette M, Shahinian A, Mak T, Watts T . Costimulation of CD28- T lymphocytes by 4-1BB ligand. J Immunol. 1997; 158(2):551-9. View

10.

Bronte V, Serafini P, Apolloni E, Zanovello P . Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother. 2002; 24(6):431-46. DOI: 10.1097/00002371-200111000-00001. View

11.

Vieweg J, Dannull J . Technology Insight: vaccine therapy for prostate cancer. Nat Clin Pract Urol. 2006; 2(1):44-51. DOI: 10.1038/ncpuro0079. View

12.

DiPaola R, Plante M, Kaufman H, Petrylak D, Israeli R, Lattime E . A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med. 2006; 4:1. PMC: 1360095. DOI: 10.1186/1479-5876-4-1. View

13.

Goodwin R, Din W, Anderson D, Gimpel S, Sato T, Maliszewski C . Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol. 1993; 23(10):2631-41. DOI: 10.1002/eji.1830231037. View

14.

Liu K, Chatta G, Twardzik D, Vedvick T, True L, Spies A . Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate cancer therapy. J Immunol. 1997; 159(1):472-80. View

15.

Gilboa E . The makings of a tumor rejection antigen. Immunity. 1999; 11(3):263-70. DOI: 10.1016/s1074-7613(00)80101-6. View

16.

Weber J . Tumor regression and autoimmunity in cytotoxic T lymphocyte-associated antigen 4 blockade-treated patients. Ann Surg Oncol. 2005; 12(12):957-9. DOI: 10.1245/ASO.2005.08.917. View

17.

Goldrath A, Luckey C, Park R, Benoist C, Mathis D . The molecular program induced in T cells undergoing homeostatic proliferation. Proc Natl Acad Sci U S A. 2004; 101(48):16885-90. PMC: 534746. DOI: 10.1073/pnas.0407417101. View

18.

JACOBS E, Haskell C . Clinical use of tumor markers in oncology. Curr Probl Cancer. 1991; 15(6):299-360. DOI: 10.1016/0147-0272(91)90005-u. View

19.

Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K . Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993; 90(8):3539-43. PMC: 46336. DOI: 10.1073/pnas.90.8.3539. View

20.

Vieweg J, Jackson A . Antigenic targets for renal cell carcinoma immunotherapy. Expert Opin Biol Ther. 2004; 4(11):1791-801. DOI: 10.1517/14712598.4.11.1791. View